Related Experiment Videos
The what, why and how of Bayesian clinical trials monitoring
L S Freedman1, D J Spiegelhalter, M K Parmar
1Biometry Branch, Division of Cancer Prevention and Control, National Institutes of Health, Bethesda, MD 20892.
Statistics in Medicine
|July 15, 1994
Abstract:
We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5-Fluorouracil for colorectal cancer.